Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Xenetic Biosciences, Inc. logo — Enhancing Lives with Transformative Therapies

Xenetic Biosciences, Inc.

Enhancing Lives with Transformative Therapies

Founded 2011 United States Framingham, United States 7 employees Post Ipo Equity Biotechnology, Health Care +1

General Information

Company Name Xenetic Biosciences, Inc.
Founded Year 2011
Location United States Framingham, United States +1
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Xenetic Biosciences, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

No funding data available for Xenetic Biosciences, Inc. yet.

Get notified when Xenetic Biosciences, Inc. raises funding

Xenetic Biosciences, Inc. Alternatives & Competitors

Xenetic Biosciences, Inc. vs
VAXIMM AG
VAXIMM AG Switzerland

Developing innovative oral T-cell immunotherapies to treat cancer patients

Grant
4 employees
Biotechnology, Health and Wellness
Xenetic Biosciences, Inc. vs
Amphivena Therapeutics
Amphivena Therapeutics

Empowering Cancer Patients with Dual-Action Immuno-Oncology Biologics

Series C
Biotechnology, Health Care
Xenetic Biosciences, Inc. vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care

FAQ About Xenetic Biosciences, Inc.

Enhancing Lives with Transformative Therapies
Xenetic Biosciences, Inc. was founded in 2011.
Xenetic Biosciences, Inc. is headquartered in Framingham, United States.
Xenetic Biosciences, Inc. operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Xenetic Biosciences, Inc. has approximately 7 employees.
Top alternatives and competitors to Xenetic Biosciences, Inc. include VAXIMM AG, Amphivena Therapeutics, ONK Therapeutics, Nkarta, Inc., ImmunoCellular Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xenetic Biosciences, Inc. and VAXIMM AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Xenetic Biosciences, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes